Infliximab treatment in pathology-confirmed neurosarcoidosis.
Daan FritzWilhelmina M C TimmermansJan A M van LaarP Martin van HagenTheodora A M SiepmanDiederik van de BeekMatthijs C BrouwerPublished in: Neurology(R) neuroimmunology & neuroinflammation (2020)
This study provides Class IV evidence that in people with pathology-confirmed neurosarcoidosis, infliximab is beneficial.
Keyphrases